Statement CSAT on Consensus statement of the European Atherosclerosis Society: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis
Authors:
Michal Vrablík; Vladimír Bláha; Renata Cífková; Tomáš Freiberger; David Karásek; Pavel Kraml; Jan Piťha; Hana Rosolová; Vladimír Soška; Tomáš Štulc; Lukáš Zlatohlávek Za Výbor Čsat; Jana Mašková
Published in the journal:
AtheroRev 2023; 8(2): 66-76
Category:
Guidelines
Zdroje
Číselné označení citované literatury odkazuje na citace v originální verzi Konsenzu:
Kronenberg F, Mora S, Stroes ESG et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur Heart J 2022: 43(39): 3925–3946. Dostupné z DOI: https://doi.org/10.1093/eurheartj/ehac361.
Štítky
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsČlánok vyšiel v časopise
Athero Review
2023 Číslo 2
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Bempedoic acid in the context of current hypolipidemic treatment options and the results of the CLEAR OUTCOMES trial
- Statement CSAT on Consensus statement of the European Atherosclerosis Society: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis
- The importance of nonstatin therapies for LDL-cholesterol lowering in the management of very high and high atherosclerotic cardiovascular risk
- Hyperlipidemic crisis as a risk factor for acute pancreatitis